Intervacc AB (publ) announced that the first batch of Strangvac, a vaccine against the highly contagious bacterial equine disease Strangles, has been released for sale in Italy. Dechra Pharmaceuticals PLC distributes the vaccine in Italy and in a number of other European countries.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.35 SEK | -3.12% | -5.54% | -31.28% |
May. 15 | Intervacc AB Announces Board Appointments | CI |
May. 15 | Intervacc AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
EPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-31.28% | 31.78M | |
+9.42% | 114B | |
+11.84% | 104B | |
-14.15% | 22.41B | |
-1.05% | 22.28B | |
-5.29% | 19.07B | |
-38.29% | 18B | |
-4.16% | 17.89B | |
+7.99% | 14.28B | |
+36.24% | 12.55B |
- Stock Market
- Equities
- IVACC Stock
- News Intervacc AB
- Intervacc AB Announces Strangvac, A Vaccine Against Equine Strangles Released for Sales in Italy